Welcome to our dedicated page for Alpha Tau Medical SEC filings (Ticker: DRTSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Alpha Tau files reports such as Form 20-F annual reports and Form 6-K current reports under the Securities Exchange Act of 1934, which together outline its clinical-stage oncology activities, financial position, and material company announcements related to the Alpha DaRT® platform.
Form 6-K filings referenced in the available data include interim consolidated financial statements, operating and financial reviews, and press releases covering topics such as clinical trial updates, investor conference participation, and corporate developments. For example, a 6-K dated August 11, 2025 attaches interim consolidated financial statements as of June 30, 2025 and an operating and financial review, and incorporates these documents by reference into Alpha Tau’s registration statements on Form F-3 and Form S-8. Other 6-Ks furnish press releases about clinical milestones, including treatment of the first patient in a U.S. multi-center pancreatic cancer trial.
Through these filings, investors can review Alpha Tau’s reported research and development expenses, marketing and general and administrative costs, net loss figures, and balance sheet data, as well as narrative discussion of factors that may affect its business. The company’s forward-looking statements sections list risks such as the need for regulatory approvals for Alpha DaRT, limited operating history, ongoing losses, funding requirements, clinical trial uncertainties, and compliance with Nasdaq listing standards and other regulations.
On Stock Titan, SEC filings for Alpha Tau can be viewed alongside AI-powered tools that summarize lengthy documents and highlight key sections, helping readers interpret interim financial statements, risk factor discussions, and exhibit lists. Users interested in DRTS and DRTSW can use this page to track the company’s furnished 6-K reports, annual 20-F filings, and related disclosures that document Alpha Tau’s clinical-stage progress and capital markets activity.
Alpha Tau Medical Ltd. announced that clinical data from two Jerusalem trials of its Alpha DaRT® alpha-radiation therapy in pancreatic cancer have been accepted for a first-ever oral presentation at Digestive Disease Week (DDW) 2026.
The abstract, led by Principal Investigator Dr. Harold Jacob, will be presented on May 2, 2026 at 10:30am (Central) in the Pancreatic Cancer I: Diagnosis and Treatment session. The work underpins Alpha Tau’s broader clinical development, including its IMPACT pilot study in the U.S. and plans toward a future pivotal study.
Alpha Tau Medical Ltd. director Avruch Michael filed an initial ownership report showing substantial equity exposure to the company. He holds 1,250,941 Ordinary Shares directly and a further 321,020 Ordinary Shares held indirectly through his spouse. He also reports 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next annual shareholders meeting, subject to continued service. In addition, he holds multiple option grants over Ordinary Shares at exercise prices ranging from $1.10 to $11.50, with expirations extending from 2027 to 2036. Some of these options are already fully vested, while others are scheduled to vest in full on the same future timeline tied to continued service.
Alpha Tau Medical Ltd. director Nadav Kidron filed an initial statement of beneficial ownership, detailing his current equity position in the company. He directly holds 2,986 ordinary shares, along with restricted share units (RSUs) covering 7,767 and 4,680 ordinary shares. The 7,767 RSUs vest in equal monthly installments over three years starting May 12, 2025, subject to continued service, while the 4,680 RSUs vest in full on the earlier of one year from March 9, 2026 or the next annual general meeting. Kidron also holds options over 35,554 ordinary shares at an exercise price of $2.79 expiring in 2035, which vest monthly over three years from May 12, 2025, and options over 15,527 shares at $6.41 expiring in 2036, vesting in full on the earlier of one year from March 9, 2026 or the next annual general meeting.
Alpha Tau Medical Ltd. director and CEO Uzi Sofer has filed an initial statement of holdings. He reports direct ownership of 1,250,941 Ordinary Shares, plus 4,680 Restricted Share Units that will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting, subject to continued service.
Sofer also holds a large portfolio of stock options over Ordinary Shares at exercise prices ranging from $1.10 to $11.50, with expirations between 2027 and 2036. According to the footnotes, some of these options are already fully vested, while others vest either in full on a one-year schedule tied to March 9, 2026 and the next Annual General Meeting, or in equal quarterly installments over four years starting January 1, 2026, all contingent on his continued service.
Alpha Tau Medical Ltd. director Alan Adler filed an initial ownership report showing his equity stake in the company. He directly holds 54,367 Ordinary Shares and 4,680 restricted share units, which will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
Adler also reports multiple option grants to acquire Ordinary Shares, with exercise prices ranging from $2.98 to $11.50 per share and expiration dates between 2028 and 2036. Some of these options are already fully vested, while others vest on the same future schedule tied to the March 9, 2026 date or the next Annual General Meeting.
Alpha Tau Medical Ltd. director Blumenfeld S. Morry filed an initial Form 3 reporting his existing equity position. He directly holds 155,771 Ordinary Shares of Alpha Tau Medical and 4,680 Restricted Share Units, which will vest in full on the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
He also reports multiple option grants over Ordinary Shares at exercise prices ranging from $2.98 to $11.50 per share, with expirations between 2028 and 2036. Footnotes indicate that some options are already fully vested, while others will vest in their entirety on the same schedule tied to March 9, 2026 or the next Annual General Meeting.
Alpha Tau Medical Ltd. director David Mark Milch filed an initial Form 3 reporting his beneficial ownership in the company. He holds several tranches of options to acquire ordinary shares, including 8,945 shares at an exercise price of $10.9200 and 10,178 shares at $7.1900, along with larger grants at lower prices that expire between 2032 and 2036.
He also reports 49,000 warrants to acquire ordinary shares held indirectly through Healthcare Capital Sponsor LLC, 29,367 ordinary shares held directly, 88,743 ordinary shares held indirectly through the same entity, and 4,680 restricted share units that will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to his continued service.
Alpha Tau Medical Ltd. director Alon Ruth filed an initial ownership report detailing his equity position in the company. He directly holds 29,367 ordinary shares, 4,680 restricted share units that vest in full upon the earlier of one year from March 9, 2026 or the next annual shareholder meeting, and multiple option grants over ordinary shares with exercise prices between $2.98 and $10.92. According to the footnotes, certain options are already fully vested, while others vest on the same future schedule as the restricted share units, all subject to his continued service.
Alpha Tau Medical Ltd. director Netser Maya filed an initial ownership report detailing current equity interests in the company. The filing shows direct ownership of 3,086 ordinary shares.
Maya also holds restricted share units representing 4,321 ordinary shares that vest in equal monthly installments over three years commencing on December 17, 2024, subject to continued service. An additional 4,680 restricted share units will vest in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, also conditioned on continued service.
The report lists stock options to acquire 24,048 ordinary shares at an exercise price of $4.05 per share, vesting in equal monthly installments over three years commencing December 17, 2024, and expiring on January 22, 2035. Further options cover 15,527 ordinary shares at an exercise price of $6.41 per share, vesting in full upon the earlier of one year from March 9, 2026 or the next Annual General Meeting of Shareholders, with an expiration date of March 9, 2036.
Alpha Tau Medical Ltd. executive Raphi Levy, the Chief Financial Officer, reports his current equity holdings in the company. He directly holds 180,180 ordinary shares, multiple option grants over ordinary shares with exercise prices ranging from 2.60 to 11.50 and expirations between 2029 and 2036, and several tranches of restricted share units.
The footnotes explain that certain restricted share unit grants vest in equal quarterly installments over three-year periods commencing January 1, 2024, January 1, 2025 and January 1, 2026, subject to his continued service. Some option grants are already fully vested, while others vest quarterly over similar three-year schedules tied to continued employment.